As of Nov 19, 2026, 1 of 2 active firms rate AVIR a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
AVIR EPS & revenue forecast
EPS · NEXT QUARTER
$-0.38
Range $-0.38 – $-0.38 · 1 analysts
Next period, 1 analysts expect Atea Pharmaceuticals Inc to earn $-0.38 a share (range $-0.38 – $-0.38), versus — a year earlier. Full-year consensus is $-1.68, growing to $-1.36 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 1 analysts · +0% YoY
Revenue is expected to reach $0 (range $0 – $0), +0.0% year-over-year. Full-year consensus is $0, rising to $30.0M next year.
Top analysts covering Atea Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on AVIR.
#1
Matthew Harrison
Morgan Stanley · Rank #393
Neutral
$7.00+75.5% to target
Overall win rate
44%
+ Follow
#2
MS
Maxwell Skor
Morgan Stanley
Neutral
$7.00+75.5% to target
Coverage
—
+ Follow
#3
AH
Andy Hsieh
William Blair
Buy
No targeton AVIR
Coverage
—
+ Follow
#4
UR
Umer Raffat
Evercore ISI
Buy
$10.00+150.8% to target
Coverage
—
+ Follow
#5
JM
Jonathan Miller
Evercore ISI
Buy
$10.00+150.8% to target
Coverage
—
+ Follow
AVIR stock forecast FAQ
What is AVIR's average 12-month price target?+
The 2 active firms with a live target average $8.50 for Atea Pharmaceuticals Inc over the next 12 months, ranging from a $10.00 high to a $7.00 low, as of Nov 19, 2026.
Is AVIR stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 1 rate it Buy or Strong Buy, 1 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for AVIR?+
The Street-high target is $10.00 (Evercore ISI Group), and the Street-low is $7.00 (Morgan Stanley). The average of all 2 active-firm targets is $8.50.
How many active Wall Street firms cover AVIR?+
2 active firms have a recognized rating on Atea Pharmaceuticals Inc as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering AVIR?+
Among analysts who currently cover AVIR, Matthew Harrison of Morgan Stanley has the strongest overall Quantellect track record (Rank #393). Their current call is Neutral with a $7.00 target.
What is Atea Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $-0.38 per share (range $-0.38 – $-0.38) across 1 analysts. Full-year EPS is projected at $-1.68, rising to $-1.36 the following year.
How much revenue is Atea Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $30.0M next year.
Have analysts been upgrading or downgrading AVIR lately?+
As of Nov 19, 2026, 1 of 2 active firms rate AVIR a Buy (1 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their AVIR calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.